ENOV Enovis CORP
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1420800 · Fiscal year ends 12/31
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.3%
TTM net income YoY61.4%
TTM EPS YoY62.1%
Revenue 3-yr CAGR11.6%
Net income 3-yr CAGR—
Margins
Gross margin61.3%
Operating margin-20.6%
Net margin-22.9%
FCF margin3.0%
EBITDA margin37.7%
Returns
ROE-30.0%
ROA-12.9%
ROIC (approx.)-12.3%
Asset turnover0.56x
Leverage & solvency
Liabilities / assets60.0%
Debt / equity0.84x
Current ratio2.15x
Interest coverage-14.69x
Cash quality & payout
Operating cash flow / net income-0.49x
Accruals ratio-19.3%
Payout ratio—
Capex / revenue8.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.25B | $2.11B | $1.71B | $1.56B | $1.43B |
| Cost of revenue | $902.79M | $926.87M | $716.42M | $693.72M | $648.51M |
| Gross profit | $1.35B | $1.18B | $990.78M | $869.38M | $777.67M |
| R&D expense | $120.33M | $91.30M | $75.33M | $60.83M | $49.09M |
| SG&A expense | $1.07B | $1.03B | $830.30M | $772.91M | $665.77M |
| Operating income | -$1.12B | -$775.72M | -$65.71M | -$71.18M | -$62.80M |
| Interest expense | $34.82M | $57.10M | $19.75M | $24.05M | $29.11M |
| Pretax income | -$1.16B | -$822.92M | -$67.13M | -$2.07M | -$121.78M |
| Income tax | $22.29M | $4.49M | -$13.29M | $36.12M | -$19.53M |
| Net income | -$1.18B | -$825.49M | -$33.26M | -$13.29M | $71.66M |
| EBITDA | $219.89M | $152.11M | $151.40M | $131.79M | $124.19M |
| EPS (basic) | -20.75 | -14.93 | -0.61 | -0.25 | 1.40 |
| EPS (diluted) | -20.75 | -14.93 | -0.61 | -0.25 | 1.40 |
| Weighted avg. shares (diluted) | 57.07M | 55.28M | 54.49M | 54.07M | 51.14M |
| Balance sheet | |||||
| Cash & equivalents | $36.39M | $48.17M | $36.19M | $24.30M | $680.25M |
| Receivables | $442.79M | $407.03M | $291.48M | $267.38M | $254.96M |
| Inventory | $584.38M | $547.12M | $468.83M | $426.64M | $356.23M |
| Current assets | $1.21B | $1.15B | $896.52M | $795.02M | $2.30B |
| PP&E, net | $507.06M | $404.50M | $270.80M | $236.74M | $235.11M |
| Goodwill | $718.30M | $1.69B | $2.06B | $1.98B | $1.93B |
| Intangibles | $1.24B | $1.32B | $1.13B | $1.11B | $1.15B |
| Total assets | $3.83B | $4.72B | $4.51B | $4.27B | $8.52B |
| Current liabilities | $598.47M | $529.00M | $369.61M | $565.20M | $1.02B |
| Short-term debt | $35.00M | $20.03M | $0 | $219.28M | $7.70M |
| Long-term debt | $1.26B | $1.31B | $466.16M | $40.00M | $2.08B |
| Total debt | $1.30B | $1.33B | $466.16M | $259.28M | $2.09B |
| Total liabilities | $2.34B | $2.15B | $1.09B | $823.45M | $3.85B |
| Shareholders' equity | $1.49B | $2.56B | $3.42B | $3.45B | $4.62B |
| Net debt | $1.26B | $1.28B | $429.97M | $234.98M | $1.41B |
| Shares outstanding | 57.19M | 55.88M | 54.60M | 54.23M | 52.08M |
| Cash flow statement | |||||
| Operating cash flow | $217.29M | $113.50M | $134.99M | -$55.86M | $356.10M |
| Capital expenditure | $197.38M | $180.71M | $122.22M | $105.45M | $104.24M |
| Free cash flow | $19.92M | -$67.21M | $12.77M | -$161.31M | $251.86M |
| Investing cash flow | -$179.37M | -$955.47M | -$242.47M | -$176.39M | -$320.48M |
| Financing cash flow | -$52.40M | $846.82M | $127.80M | -$465.13M | $584.91M |
| Depreciation & amortization | $1.34B | $927.83M | $217.11M | $202.97M | $186.99M |
| Stock-based compensation | $32.92M | $29.66M | $34.06M | $38.95M | $35.35M |
| Share buybacks | $3.50M | $4.77M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.